March 18, 2026 — San Francisco-based startup Mave Health has begun pre-orders for a $495 wearable headset designed to improve attention, mood, and stress regulation through brain stimulation. The device uses transcranial direct current stimulation (tDCS), positioning itself in a growing market of consumer neuromodulation products.
From Personal Tragedy to Tech Startup
Founder Dhawal Jain said the idea for Mave Health originated from a personal tragedy during the COVID-19 pandemic lockdowns. His flatmate’s fiancée died by suicide, an event that led Jain and his co-founders, Jai Sharma and Aman Kumar, to question existing mental health approaches.
“We started connecting with psychologists and were getting the same answers,” Jain explained. “We felt there was no tangible way to measure progress in the mental health space.” This frustration prompted the team to explore neuroscience and neuromodulation technologies.
Technology and Positioning
The Mave Health headset employs tDCS, a non-invasive technique that delivers a low 1-2 mA current to stimulate neurons. The company recommends daily 20-minute sessions for the first few weeks of use. An accompanying app tracks long-term trends in mood, focus, and stress, and can integrate with other health data like Heart Rate Variability (HRV).
Critically, Mave Health has positioned the device as a non-medical lifestyle product. This strategic choice allows it to be sold in the United States without clearance from the U.S. Food and Drug Administration (FDA). Jain stated this approach aims to reach a wider audience beyond clinical populations.
Research and Expert Perspectives
The company has not conducted formal clinical trials or published peer-reviewed studies. However, Jain cited private beta testing in 2024 and 2025 involving over 500 users. In that testing, the startup reported 80% of users noted a 60% increase in productivity, and 75% reported reduced stress within two months.
Mave Health said it has four observational studies across 200 participants under academic review, with an aim to publish in 2026.
Dr. Himanshu Nirvan, a Delhi-based psychiatrist who consulted with Mave Health, described tDCS-based devices as a proven modality for mental health issues. “For a lot of people, tDCS is actually quite a good modality, considering that it’s a very portable device,” Dr. Nirvan said.
Leigh Elkin Charvet, a clinical neuropsychologist and Professor of Neurology at NYU Grossman School of Medicine, provided context on the technology’s broader use. In an email statement, she noted tDCS is considered safe and effective for neuromodulation but highlighted a key challenge.
“One challenge is that consumers may use the device without clinical screening or clear guidance about whether it is appropriate for their symptoms,” Charvet said. She added that using tDCS for broad lifestyle enhancement in healthy individuals has not been widely studied, with most strong research focused on clinical populations.
Funding and Availability
Mave Health recently secured $2.1 million in a seed funding round led by Blume Ventures. Individual investors, including Tesla Autopilot AI lead Dhaval Shroff, also participated. Total funding to date is just under $3 million.
The headset is currently available for pre-order. The company aims to ship its first batch to customers in the U.S. and India in April 2026. The wearable weighs approximately 100 grams, and side effects are reported as mild and temporary, such as itching or discomfort.
What’s Next for Consumer Neuromodulation
The launch places Mave Health among a fleet of startups targeting wellness and mental health with wearable stimulation devices. The sector’s growth hinges on consumer adoption and the ongoing debate about the efficacy of such technologies for non-clinical, lifestyle purposes. The company’s planned observational studies and future user data will be closely watched for evidence of the headset’s long-term impact.
For more information on neuromodulation, see the National Institute of Mental Health’s overview of brain stimulation therapies. Details on tDCS research can be found through ClinicalTrials.gov.
This article was produced with AI assistance and reviewed by our editorial team for accuracy and quality.
